Med. praxi. 2023;20(3):135-140 | DOI: 10.36290/med.2023.020

Biologic treatment of migraine

MUDr. Petra Migaµová
Centrum pro diagnostiku a léčbu bolestí hlavy, Neurologická klinika FN Ostrava a LF Ostrava

Migraine is the third most common neurological disease. It is also one of the most disabling diseases in the world. About a billion people are suffering from migraine around the world. There are around one million patients with migraine in the Czech Republic. At least 50 000 women and men suffer from chronic migraine. Since 1993, we have had a specific acute antimigraine drug, triptans. Since 2020, targeted biological treatment has been available, which significantly reduces the number of migraine attacks and improves the patient's quality of life. Since 2022 another acute and prophylactic treatment, gepanty, is available.

Keywords: episodic and chronic migraine, prophylactic treatment, anti­‑CGRP treatment, gepants.

Accepted: May 18, 2023; Published: June 15, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Migaµová P. Biologic treatment of migraine. Med. praxi. 2023;20(3):135-140. doi: 10.36290/med.2023.020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Neľádal T. Chronická migréna. Neurol. praxi. 2019;20(2): 115-120. Go to original source...
    2. Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50 s. J Headache Pain. 2016 Dec;17(1):104. doi: 10.1186/s10194-016-0699-5. Epub 2016 Nov 14. PMID: 27844455; PMCID: PMC5108738. Go to original source... Go to PubMed...
    3. Recober A. Pathophysiology of Migraine. Continuum (Minneap Minn). 2021 Jun 1;27(3):586-596. doi: 10.1212/CON.0000000000000983. PMID: 34048393. Go to original source... Go to PubMed...
    4. Kotas R. Bolesti hlavy v klinické praxi. Praha: Maxdorf; 2015.
    5. Barbanti P, Brighina F, Egeo G, et al. Migraine as a Cortical Brain Disorder. Headache. 2020 Oct;60(9):2103-2114. doi: 10.1111/head.13935. Epub 2020 Aug 26. PMID: 32851650. Go to original source... Go to PubMed...
    6. Honkasalo ML, Kaprio J, Winter T, et al. Migraine and concomitant symptoms among 8167 adult twin pairs. Headache. 1995 Feb;35(2):70-8. doi: 10.1111/j.1526-4610.1995.hed3502070.x. PMID: 7737864. Go to original source... Go to PubMed...
    7. Mathew NT. Pathophysiology of chronic migraine and mode of action of preventive medications. Headache. 2011 Jul­‑Aug;51 Suppl 2:84-92. doi: 10.1111/j.1526-4610.2011.01955.x. PMID: 21770930. Go to original source... Go to PubMed...
    8. Chu LF, Angst MS, Clark D. Opioid­‑induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain. 2008 Jul­‑Aug;24(6):479-96. doi: 10.1097/AJP.0b013e31816b2f43. PMID: 18574358. Go to original source... Go to PubMed...
    9. Diener HC, Tfelt­‑Hansen P, Dahlöf C, et al; MIGR-003 Study Group. Topiramate in migraine prophylaxis--results from a placebo­‑controlled trial with propranolol as an active control. J Neurol. 2004 Aug;251(8):943-50. doi: 10.1007/s00415-004-0464-6. PMID: 15316798. Go to original source... Go to PubMed...
    10. Russo M, De Rosa MA, Calisi D, et al. Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits. Int J Mol Sci. 2022 Sep 27;23(19):11418. doi: 10.3390/ijms231911418. PMID: 36232720; PMCID: PMC9569564. Go to original source... Go to PubMed...
    11. Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine­‑preventive medications among patients with chronic migraine. Cephalalgia. 2015 May;35(6):478-88. doi: 10.1177/0333102414547138. Epub 2014 Aug 27. PMID: 25164920. Go to original source... Go to PubMed...
    12. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990 Aug;28(2):183-7. doi: 10.1002/ana.410280213. PMID: 1699472. Go to original source... Go to PubMed...
    13. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990 Aug;28(2):183-7. doi: 10.1002/ana.410280213. PMID: 1699472. Go to original source... Go to PubMed...
    14. Edvinsson L. Role of CGRP in Migraine. Handb Exp Pharmacol. 2019;255:121-130. doi: 10.1007/164_2018_201. PMID: 30725283. Go to original source... Go to PubMed...
    15. Hargreaves R, Olesen J. Calcitonin Gene­‑Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class. Headache. 2019 Jun;59(6):951-970. doi: 10.1111/head.13510. Epub 2019 Apr 25. PMID: 31020659. Go to original source... Go to PubMed...
    16. Ehrlich M, Hentschke C, Sieder C, Maier­‑Peuschel M, Reuter U. Erenumab versus topiramate: post hoc efficacy analysis from the HER­‑MES study. J Headache Pain. 2022 Nov 15;23(1):141. doi: 10.1186/s10194-022-01511-y. PMID: 36380284; PMCID: PMC9664641. Go to original source... Go to PubMed...
    17. Tepper D. Gepants. Headache: The Journal of Head and Face Pain. 2020;60(5):1037-1039. doi: 10.1111/head.13791. Go to original source... Go to PubMed...
    18. Schuster NM, Rapoport AM. New strategies for the treatment and prevention of primary headache disorders. Nat Rev Neurol. 2016 Oct 27;12(11):635-650. doi: 10.1038/nrneurol.2016.143. PMID: 27786243. Go to original source... Go to PubMed...
    19. Moriarty M, Mallick­‑Searle T, Barch CA, et al. Monoclonal Antibodies to CGRP or Its Receptor for Migraine Prevention. JNP. October 15; 2019. doi: https://doi.org./10.1016.j.nurpra.2018. 07. 009. Go to original source...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.